{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:15:43Z","timestamp":1785708943953,"version":"3.56.0"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,1,1]]},"abstract":"<jats:p>Introduction. 4-Aminopyridine (4-AP) is a potassium channel blocker used to increase muscle strength in the treatment of demyelinating diseases such as multiple sclerosis. We describe a case of ingestion by an 8-month-old child that resulted in severe but transient symptoms.<\/jats:p>\n               <jats:p>Case Report. An 8-month-old boy was found with greenish saliva, and a capsule with green 4-AP powder was missing. On arrival to an emergency department, he was jittery, tachycardic, and tachypneic. Activated charcoal, a cathartic, and midazolam (0.5 mg\/kg) were administered before transfer to a tertiary pediatric hospital. On arrival, the infant remained tachycardic and tachypneic. His eyes deviated upward and he was noted to have 3+ deep tendon reflexes bilaterally. He was administered 0.9% normal saline (20 mL\/kg) for a wide pulse pressure with low diastolic blood pressure. The patient developed dramatic opisthotonic posturing and vermiform tongue fasciculations. The symptoms responded well to repeated intravenous doses of benzodiazepines. In this case, we used 2 doses of lorazepam (0.05 mg\/kg each). During opisthotonic posturing, an electroencephalogram performed in the intensive care unit revealed no evidence of seizure activity. Within 20 hours after admission, the patient became asymptomatic.<\/jats:p>\n               <jats:p>Conclusion. This case is, to our knowledge, the first documented pediatric 4-AP ingestion. Clinical signs and symptoms are described as well as the response to therapy with benzodiazepines. The electroencephalogram performed while the patient was symptomatic was negative for seizures.<\/jats:p>","DOI":"10.1542\/peds.111.1.e82","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"e82-e84","source":"Crossref","is-referenced-by-count":12,"title":["Opisthotonic Posturing With Neuromuscular Irritability Attributable to 4-Aminopyridine Ingestion by a Healthy Pediatric Patient"],"prefix":"10.1542","volume":"111","author":[{"given":"Larissa","family":"Velez","sequence":"first","affiliation":[{"name":"North Texas Poison Center, Dallas, Texas"},{"name":"University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Shirazi","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"Goto","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital and Health Center San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greene","family":"Shepherd","sequence":"additional","affiliation":[{"name":"North Texas Poison Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"Roth","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,1,1]]},"reference":[{"key":"2021120821104592100_R1","doi-asserted-by":"crossref","unstructured":"Meves H, Pichon Y. The effect of internal and external 4-aminopyridine on the potassium currents in intracellularly perfused squid giant axons. J Physiol.1977;268:511\u2013532","DOI":"10.1113\/jphysiol.1977.sp011869"},{"key":"2021120821104592100_R2","doi-asserted-by":"crossref","unstructured":"Sherrat RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature.1980;283:570\u2013572","DOI":"10.1038\/283570a0"},{"key":"2021120821104592100_R3","doi-asserted-by":"crossref","unstructured":"Thesleff S. Aminopyridines and synaptic transmission. Neuroscience.1980;5:1413\u20131419","DOI":"10.1016\/0306-4522(80)90002-0"},{"key":"2021120821104592100_R4","doi-asserted-by":"crossref","unstructured":"Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. J Toxicol Clin Toxicol.1980;16:487\u2013497","DOI":"10.3109\/15563658008989978"},{"key":"2021120821104592100_R5","doi-asserted-by":"crossref","unstructured":"Davis FA, Stefoski D, Rush J. Orally administered 4-AP improves clinical signs in multiple sclerosis. Ann Neurol.1990;27:186\u2013192","DOI":"10.1002\/ana.410270215"},{"key":"2021120821104592100_R6","doi-asserted-by":"crossref","unstructured":"van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-AP on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol.1992;32:123\u2013130","DOI":"10.1002\/ana.410320203"},{"key":"2021120821104592100_R7","doi-asserted-by":"crossref","unstructured":"Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology.1981;31:265\u2013271","DOI":"10.1212\/WNL.31.3.265"},{"key":"2021120821104592100_R8","doi-asserted-by":"crossref","unstructured":"Lundh H, Nilsson O, Rosen I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry.1979;42:171\u2013175","DOI":"10.1136\/jnnp.42.2.171"},{"key":"2021120821104592100_R9","doi-asserted-by":"crossref","unstructured":"Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci.1983;60:353\u2013362","DOI":"10.1016\/0022-510X(83)90145-4"},{"key":"2021120821104592100_R10","doi-asserted-by":"crossref","unstructured":"Stefoski D, Davis FA, Fitssimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-aminopyridine in multiple sclerosis: prolonged administration. Ann Neurol.1991;41:1344\u20131348","DOI":"10.1212\/WNL.41.9.1344"},{"key":"2021120821104592100_R11","doi-asserted-by":"crossref","unstructured":"Booij LH, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium blockade in man. Anesth Analg.1978;57:316\u2013321","DOI":"10.1213\/00000539-197805000-00007"},{"key":"2021120821104592100_R12","doi-asserted-by":"crossref","unstructured":"Agoston S, Maestrone E, van Hezik EJ, et al. Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest.1984;73:1291\u20131296","DOI":"10.1172\/JCI111331"},{"key":"2021120821104592100_R13","doi-asserted-by":"crossref","unstructured":"Gay R, Angeo S, Lee R, et al. Treatment of verapamil intoxication in intact dogs. J Clin Invest.1986;77:1805\u20131811","DOI":"10.1172\/JCI112505"},{"key":"2021120821104592100_R14","doi-asserted-by":"crossref","unstructured":"ter Wee PM, Kremer Hovinga TK, Uges DR, van der Geest S. 4-Aminopyridine and hemodialysis in the treatment of verapamil intoxication. Hum Toxicol.1985;4:327\u2013329","DOI":"10.1177\/096032718500400315"},{"key":"2021120821104592100_R15","doi-asserted-by":"crossref","unstructured":"Soni M, Kam P. 4-Aminopyridine\u2014a review. Anaesth Intens Care.1982;10:120\u2013126","DOI":"10.1177\/0310057X8201000205"},{"key":"2021120821104592100_R16","doi-asserted-by":"crossref","unstructured":"Evenhuis J, Agoston S, Salt PJ, De Lange AR, Wouthuyzen W, Erdmann W. Pharmacokinetics of 4-aminopyridine in human volunteers. Br J Anaesth.1981;53:567","DOI":"10.1093\/bja\/53.6.567"},{"key":"2021120821104592100_R17","doi-asserted-by":"crossref","unstructured":"Bever CT, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, cross-over trial. Neurology.1994;44:1054\u20131059","DOI":"10.1212\/WNL.44.6.1054"},{"key":"2021120821104592100_R18","doi-asserted-by":"crossref","unstructured":"Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol.1994;32:583\u2013587","DOI":"10.3109\/15563659409011063"},{"key":"2021120821104592100_R19","doi-asserted-by":"crossref","unstructured":"Pickett TA, Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med.1996;27:382\u2013385","DOI":"10.1016\/S0196-0644(96)70277-9"},{"key":"2021120821104592100_R20","doi-asserted-by":"crossref","unstructured":"van Diemen HA, Polman CH, Koetsier JC, van Loenen AC, Nauta JJ, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum levels related to efficacy and safety. Clin Neuropharmacol.1993;16:195\u2013204","DOI":"10.1097\/00002826-199306000-00002"},{"key":"2021120821104592100_R21","doi-asserted-by":"crossref","unstructured":"Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 3, 4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J Toxicol Clin Toxicol.1995;33:249\u2013251","DOI":"10.3109\/15563659509017992"},{"key":"2021120821104592100_R22","doi-asserted-by":"crossref","unstructured":"Yamaguchi S, Rogawski MA. Effects of anticonvulsant drugs on 4-aminopyridine- induced seizures in mice. Epilepsy Res.1992;11:9\u201316","DOI":"10.1016\/0920-1211(92)90016-M"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/1\/e82\/1005983\/pe0103000e82.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/1\/e82\/1005983\/pe0103000e82.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T01:11:19Z","timestamp":1639012279000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/111\/1\/e82\/28546\/Opisthotonic-Posturing-With-Neuromuscular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,1,1]]},"published-print":{"date-parts":[[2003,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.111.1.e82","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,1]]}}}